Other News To Note
Wednesday, April 13, 2011
Ensemble Therapeutics Corp., of Cambridge, Mass., triggered a milestone payment from partner Bristol-Myers Squibb Co., of Princeton, N.J., by developing an Ensemblin-based therapeutic against one of the targets in their collaboration. Achievement of the milestone was based on specific criteria of the drug, including potency, selectivity and pharmacokinetics. That drug target program will now transition to BMS for development.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.